

Manuscript Title: Facility-based HIV self-testing as an additional testing option in health facilities: A systematic review and meta-analysis

Kathleen McGee^{S1}, Muhammad S. Jamil², Nandi Siegfried³, Busisiwe Msimanga Radebe⁴, Magdalena Barr-DiChiara⁵, Rachel Baggaley⁵, Cheryl Johnson⁵

1. Independent public health consultant, Dakar, Senegal
2. Regional Office to the Eastern-Mediterranean Region, World Health Organization, Cairo, Egypt
3. Independent clinical epidemiologist, Cape Town, South Africa
4. World Health Organization, Johannesburg, South Africa
5. Global HIV, Hepatitis and STIs Programme, World Health Organization, Geneva, Switzerland

§. Corresponding author: Kathleen McGee

36 OKM 272, Ouakam Cite Assemblee

Dakar, 123000, Senegal

+(221)785927029

kat.v.mcgee@gmail.com

MSJ: mjamil@who.int

NS: nandisiegfried@gmail.com

BMR: msimangaradebeb@who.int

MBDC: barrdichiam@who.int

RB: baggaleyr@who.int

CJ: johnsonc@who.int

Keywords: HIV Testing; HIV self-testing; systematic review; meta-analysis; costs and cost analysis

Word count:

Abstract: 350/350

Main text: 3661/5000

1 **Abstract** (word count: 295/300 words)

2 Facility-based HIV self-testing (FB-HIVST) has been used across settings to improve testing accessibility
3 and achieve global testing and treatment targets by 2030. The effectiveness of FB-HIVST remains
4 uncertain; thus, we conducted a review to assess the risk and benefits of FB-HIVST to inform global
5 guidance. We searched across nine electronic databases covering the period up to February 01, 2022,
6 and included publications that directly compared FB-HIVST to standard HIV testing services (SOC) or no
7 intervention. Meta-analysis was conducted on comparable outcomes using random-effects model for
8 relative risks (RR) and 95% confidence intervals. Other outcomes were summarized descriptively. Risk of
9 bias was assessed using Cochrane’s Risk of Bias tool. Certainty of evidence was assessed using Grading of
10 Recommendations, Assessment, Development and Evaluations (GRADE). After screening 2,203 articles,
11 11 studies were found eligible, including 4 randomized controlled trials (RCT), 2 cohort studies, 3
12 economic evaluations, and 2 qualitative studies. Meta-analyses of four RCTs demonstrated that FB-HIVST
13 may increase testing uptake (RR=2.47; 95% CI= 0.96, 6.33) and may lead to greater HIV diagnosis
14 (RR=3.77; 95% CI=0.81, 17.44). Overall GRADE certainty was low. Trials found FB-HIVST as acceptable and
15 feasible to many users, with minimal risk of social harm. A single RCT reported on linkage to care and
16 observed that, among total enrolled, FB-HIVST compared to SOC may increase linkage to care threefold
17 (RR= 3.26; 95% CI: 0.68, 15.62; low-certainty evidence). FB-HIVST was found to be cost-effective in a
18 high-burden outpatient department, but determined to be quite variable. FB-HIVST is safe and may be
19 an effective method to increase testing coverage and the diagnoses, particularly in high-burden HIV
20 settings or sites with limited staff and resources. Findings from this review informed WHO’S guideline
21 development process and its recommendation that FB-HIVST be offered as an additional testing option
22 at facilities.

23

24 PROSPERO Number: CRD42022302619

25

26

27 **Main Manuscript (word count: 3661 words)**

28 **Introduction**

29 Since 2016, the World Health Organization (WHO) has recommended HIV self-testing (HIVST) as a safe
30 and effective HIV testing option [1], whereby an individual collects their own specimen, using a rapid
31 finger-prick or oral fluid-based test, performs the test, and interprets their result, with or without
32 provider assistance. Since then, the range of WHO-prequalified HIVST products has expanded [2], and
33 over 100 countries have integrated HIVST into their national policies and programmes [3]. Many different
34 service delivery models for HIVST have been rolled out worldwide to better reach people with HIV who
35 do not know their status, as well as to make testing easy for people with ongoing HIV risks. Numerous
36 self-testing approaches have been shown to be effective testing strategies, such as distribution in
37 communities, workplaces, faith-based settings, online via mail, retail outlets, pharmacies, vending
38 machines, and secondary distribution to partners or peers [4–6].

39 In high-burden HIV settings, distribution of HIVST kits in health facilities has been used to increase
40 testing coverage [4]. During the COVID-19 pandemic, many health facilities offered HIVST to maintain
41 testing services while mitigating added strain on limited human resources [5,6]. Prior to the pandemic,
42 some programmes began to use risk-screening tools among adults and adolescents to address limited
43 resources and focus HIV testing to specific risk factors [7]. Risk screening tools have been especially
44 explored for provider-initiated testing and counselling (PITC) in east and southern Africa. Despite the
45 potential for optimizing resources by targeting testing, recent evidence suggests they may have
46 contributed to missing cases and undermine global HIV goals [8]. To date, WHO does not recommend
47 the use of “screen-out” tools that are designed to exclude low-risk people from routine HTS. However, a
48 recent systematic review suggests that “screen-in” risk-based tools may be useful in settings where the
49 routine offer of HTS is not currently available or feasible and could be further optimised with facility-
50 based HIVST (FB-HIVST) [7].

51 As programmes seek to optimise increasingly limited resources for HIV testing services, policy makers
52 and implementers are grappling with whether FB-HIVST should be considered [9]. To support the World
53 Health Organization (WHO) in updating existing HIVST guidance and understand the potential benefits
54 and risks of FB-HIVST uses, we conducted a systematic review of the literature. This review informed the
55 2023 consolidated guidelines on HIV testing services.

56

57 **Materials and Methods**

58 The review protocol was registered online in the International prospective register of systematic reviews
59 (PROSPERO 2022 CRD42022302619).

60 **Search strategy and inclusion criteria**

61 We searched nine electronic databases including Ovid Medline, Embase, CINAHL Plus, EconLit, Global
62 Health, PsycInfo, Cochrane Library, Web of Science, and Scopus through January 2022. We also verified
63 secondary references on studies included in the review as well as on previously published review articles
64 relevant to HIVST. Experts in the field were contacted to identify additional articles and validate inclusion
65 criteria. As previously stated, this paper presents the results as they were presented to WHO's guideline
66 development group in November 2022 leading to WHO guideline recommendations in July 2023.

67

68 The search strategy was adapted to each database using key terms "HIV", "self-test" (Appendix 1,
69 Supplementary material). HIVST in any type of health facility setting were eligible, with the exception of
70 secondary distribution. No restrictions were placed based on study location or language of the article.
71 Two reviewers screened studies and differences in judgement were resolved by other review team
72 members. To be included in the review, a study had to directly compare FB-HIVST to standard HIV testing
73 services (HTS), or no intervention, and report on one or more of the following outcomes: (1) HIV testing

74 uptake (defined as proportion of participants tested for HIV in study period); (2) HIV positivity
75 (proportion of people tested and confirmed positive); (3) linkage to care (proportion of people tested
76 positive linked to confirmatory testing, clinical assessment or treatment); (4) social harm/adverse events
77 (occurrence and reporting of any harm or undesirable experience occasioned by the intervention); (5)
78 acceptability of FB-HIVST (proportion of participants who reported intervention as acceptable); (6)
79 diagnostic accuracy (measured by specificity, sensitivity, positive predictive values, and negative
80 predictive values); (7) Feasibility (proportion of participants who reported intervention as easy to use);
81 (8) values and preferences (reported facilitators and barriers associated with the intervention), (9) costs
82 and cost-effectiveness.


83 **Data analysis**

84 Data was extracted by one reviewer using an Excel-based data extraction form. Risk of bias was assessed
85 according to Cochrane Guidance [10]. Pair-wise meta-analysis was conducted on comparable outcomes,
86 when possible, using REVMAN 5.4.1, using random-effects model for relative risk (RR), with 95%
87 confidence intervals (CI). Following guidance from GRADE Handbook [11], overall certainty of evidence
88 was rated by appraising risk of bias, level of imprecision, indirectness, inconsistency and other
89 considerations. In accordance with WHO guideline development protocol, we report the results using
90 GRADE recommended language which integrates the clinical importance of the estimate of effect with
91 the overall certainty of the estimate [12]. Evidence relating to values and preferences such as perceived
92 benefits and barriers, reasons for uptake or choice of testing, and participant recommendations were
93 summarized qualitatively. Full RoB and GRADE Quality Assessment is available in (Supplementary
94 material).

95 **Results**

96 The searches yielded 2,203 citations, of which, 11 studies were deemed eligible, including 4 randomized
 97 controlled trials [4,13–15], 2 prospective single-arm cohort studies [16,17], 2 qualitative studies
 98 employing individually-based in-depth interviews (IDI) [18,19], 2 costing studies [20,21] and 1 cost-
 99 effective analysis [22] (Figure 1).

100 **Figure 1. Prisma Diagram**



101
 102 Among the 4 RCTs, Dovel 2020 [4], a cluster RCT, served as a parent trial for subsequent studies in
 103 Malawi, including a costing study [20], a modelled cost-effectiveness study [22], and a qualitative study
 104 [18], targeting adolescent & adult outpatients in high burden health facilities. The remaining RCTs [13–
 105 15] were individual RCTs, targeting truck drivers and female sex workers at roadside wellness clinics in
 106 Kenya. Additional studies were set in a U.S. emergency department (ED) [16], youth-friendly hospitals in
 107 Mozambique [17], health facilities in Malawi [19], and ante-natal clinics (ANC) and out-patient
 108 departments (OPD) in Zambia and Zimbabwe [21], targeting adult and adolescent outpatients. All studies
 109 used oral fluid-based HIV rapid diagnostic tests for self-testing, providing participants with free test kits
 110 and manufacturer-provided instructions. See Table 1. for further information on studies’ implementation
 111 details.

112 **Table 1. Summary of included study characteristics (n=11)**


Study ID	Study Type	Country	Population	Facility Type	Implementation details
Dovel et al, 2020 [4]	RCT, cluster	Malawi	Adolescents & adult outpatients (n=5,885) (n=57)	OPD	Sensitization, in-person demonstration, private booth and optional provider assistance
Nichols et al, 2020 [20]	Cost				
Nichols et al, 2021 [22]	CEA				
Mphande et al, 2021 [18]	Qualitative, IDI				
Kelvin et al, 2018 [13]	RCT, ind	Kenya	Truck drivers (n=305)	Roadside wellness clinics	In-person demonstration, optional provider assistance
Kelvin et al, 2019 (a) [14]	RCT, ind	Kenya	Truck drivers (n=2,262)	Roadside wellness clinics	Sensitization, in-person demonstration, and optional provider assistance
Kelvin et al, 2019 (b) [15]	RCT, ind	Kenya	Female sex workers (n=2,196)	Roadside wellness clinics	Sensitization, in-person demonstration, and optional provider assistance
Gaydos et al, 2013 [16]	Cohort, prospective, single-arm	USA	Adult outpatients (n=473)	ED	Private booth
Hector et al, 2018 [17]	Cohort, prospective, single-arm	Mozambique	Adolescents (n=496)	Youth-friendly hospitals	Sensitization, in-person demonstration, private booth
Sande et al, 2021 [21]	Cost	Zambia, Zimbabwe	OPD clients	ANC, OPD	Sensitization, in-person demonstration, private booth and provider assistance
Hubbard et al, 2022 [19]	Qualitative, IDI	Malawi	Adolescents & adult positive testers (n=27)	Health facilities	N/A

RCT: randomized control trial; CEA: cost-effectiveness analysis; IDI: in-depth interviews; OPD: outpatient department; ANC: ante-natal clinic; ED: Emergency department; N/A: non-applicable

113 **HIV Testing Uptake**

114 Four RCTs [4,13–15] reported on HIV testing uptake. A meta-analysis showed that FB-HIVST may improve
 115 HIV testing uptake compared to standard HTS (RR= 2.47; 95% CI: 0.96, 6.33; $\text{Chi}^2 = 187.21$; $\text{df} = 3$;
 116 $p < 0.00001$; $I^2 = 98\%$, low certainty evidence). In absolute numbers, there were over twice as many
 117 testers in the FB-HIVST arms compared to testers in the standard of care (SOC) arm.

Figure 1. HIV testing uptake among participants offered FB-HIVST vs. HTS



Footnotes

(1) Adjusted for cluster effect using reported ICC. Dovel, 2020 additionally reports an Adjusted OR(95% CI) for site: 8.89(4.17-18.94);...

FB-HIVST: Facility-based HIV self-testing; CI: Confidence Interval; SOC: standard of care; M-H: Mantel-Haenszel; OR: odds ratio

118
 119 The overall certainty was rated as low due to a high risk of bias combined with the non-statistical
 120 significance of the pooled effect. High levels of statistical heterogeneity were driven by Kelvin, 2018,
 121 where the study population did not receive any sensitization about HIV testing or HIVST (Appendix 2,
 122 Supplementary materials). In the three other RCTs, sensitization included a 10-minute health talk to all
 123 outpatients present in the waiting room, and text messages on the importance of HIV testing.

124 The test for subgroup differences between population types didn't present a statistically significant
 125 subgroup effect. Rather, subgroup analysis showed FB-HIVST may increase HIV testing uptake among
 126 both the general population and key population groups, compared to standard testing alone. In a single
 127 RCT conducted among a general population [4] FB-HIVST resulted in nearly a four-fold increase in HIV
 128 testing uptake compared to standard testing (RR= 3.98; 95% CI: 3.26-4.85, low-certainty evidence).


129 Subgroup analysis of three RCTs [13–15] conducted among key and priority populations, determined that

130 FB-HIVST could potentially double testing uptake compared to standard testing, however the effects are
 131 uncertain due to very low-certainty evidence (RR= 2.07; 95% CI: 0.86, 4.97; Chi2 = 43.63; df = 2;
 132 p<0.00001; I2 = 95%).

133 **HIV Positivity**

134 All four RCTs reported on HIV positivity [4,13–15]. A meta-analysis of these studies determined FB-HIVST
 135 may likely diagnose more people with HIV compared to standard HTS (RR= 3.77; 95% CI: 0.81,17.44; Chi²
 136 = 4.67; df =3 ; p<0.20; I² = 36%; low-certainty evidence). Certainty was again downgraded to low due to
 137 high risk of bias and a large confidence interval crossing the line of no effect, thus driving imprecision. In
 138 absolute numbers, FB-HIVST diagnosed more than five times as many people with HIV than standard
 139 HTS. Observed heterogeneity was driven by Kelvin 2018 [13], which, unlike other studies, did not provide
 140 any sensitization on HIV testing.

141 **Figure 2. HIV Positivity**



Footnotes

(1) Adjusted for cluster effect using reported ICC. Dovel, 2020 additionally reports an Adjusted OR(95% CI) for site: 1.10(0.45-2.69);...

FB-HIVST: Facility-based HIV self-testing; CI: Confidence Interval; SOC: standard of care; M-H: Mantel-Haenszel; OR: odds ratio

142
 143 Subgroup analysis suggests that, when compared to standard HTS, there is very low-certainty evidence
 144 that FB-HIVST plus sensitization could potentially increase the number people with HIV diagnosed
 145 (Appendix 2, Supplementary materials). HIV positivity could also be higher when using FB-HIVST, instead
 146 of standard HTS alone, in the general outpatient population in a high HIV burden setting (RR= 5.12; 95%
 147 CI: 1.14, 23.00). However, FB-HIVST could make little to no difference on HIV positivity in clinics reaching

148 key and priority populations when compared to standard testing (RR= 2.97; 95% CI: 0.23, 37.65 ; Chi² =
149 4.48; df = 2; p<0.11; I² = 55%).

150
151 Other subgroup analysis revealed no other clear factors driving heterogeneity (Appendix 2,
152 Supplementary materials).

153 **Linkage to HIV Care**

154 Only one RCT [4] reported on linkage to care and reported that FB-HIVST, compared to standard HTS,
155 may increase the number of people linked to HIV care after three-months three-fold (RR= 3.26; 95% CI:
156 0.68, 15.62). This effect was driven by the high number of people tested and diagnosed with HIV in the
157 study which took place in an outpatient department. When the analysis was limited to those newly
158 diagnosed with HIV, however, there was no difference in linkage rates between FB-HIVST and standard
159 HTS (RR= 0.81; 95% CI: 0.52-1.26) (Appendix 2, Supplementary materials). Overall, there was low-
160 certainty evidence that FB-HIVST could enable more people with HIV to link to care overall or at least
161 achieve linkage rates comparable to standard testing services.

162 **Social harm**

163 Social harm was only reported in one RCT [4] which found harms to be rare, particularly for FB-HIVST
164 compared to SOC. In this study participants were asked about harms when testing, including if they
165 experienced coercion or pressure to test and disclose results. More participants reported that they
166 experienced pressure to test (n=10) or to share their test results (n=1) in provider testing, while no
167 participants receiving FB-HIVST reported experiencing such pressure. Thus, there is low-certainty
168 evidence that FB-HIVST does not increase social harm and may even result in fewer harms compared to
169 standard facility-based testing.

170

171 **Acceptability**

172 Acceptability of FB-HIVST was reported by all four RCTs [4,13–15], and all studies found that, when
173 compared to standard testing, most individuals would probably prefer FB-HIVST (moderate-certainty
174 evidence).

175 In one study among individuals in general outpatient departments [4], those receiving FB-HIVST were
176 more likely to test again (RR= 1.21; 95% CI: 1.10-1.33) and more likely to recommend testing to friends
177 (RR= 1.12; 95% CI: 1.04-1.21) compared to standard facility-based HTS. In RCTs among key (female sex
178 workers) and vulnerable populations (long-distance truck drivers) [13–15], FB-HIVST was also slightly
179 more preferred when compared with both home-based HIVST and standard testing (FB-HIVST: 16.8%,
180 151/900, home-based HIVST: 4.0%, 36/900, standard testing: 10.3%, 93/900).

181
182 **Feasibility and diagnostic accuracy**

183 No RCTs reported on feasibility and accuracy related outcomes. Thus, findings were derived from two
184 observational cohort studies [16,17]. With 75.33% (n=577/766) of pooled participants reporting HIVST
185 easy to use, both studies found that adolescent and adult users (16 to 64 years old) generally found FB-
186 HIVST feasible [16,17]. However ease of use appeared highest among adults in emergency departments
187 in the USA (99%, n=463/467) [16].

188
189 Only one study reported on the accuracy and performance of FB-HIVST compared to confirmatory finger-
190 prick HIV test [17] The study reported acceptable sensitivity (100%, 95%CI: 99-100%) and specificity
191 (100%, 95%CI: 48-100%). No false negative or false positive results were identified, but confidence
192 intervals around specificity were particularly wide due to small numbers. Additionally, there were six
193 reports of inconclusive or invalid results identified: two nonreactive self-test results which were reported
194 as inconclusive following provider-delivered testing and four invalid self-tests which were either

195 confirmed negative (3) or were inconclusive (1) following provider-delivered testing. The study did not
196 specify whether invalid testers were already on anti-retroviral treatment.

197
198 **Values and preferences**

199 Five studies, including 2 RCTs [4,13], 1 cohort [17], and 2 qualitative studies [18,19], reported on some
200 aspect of user values and preferences for FB-HIVST among adult outpatients, truckers, adolescents
201 between ages 16-20, and men who tested HIV positive. In all studies, most reported that FB-HIVST was
202 acceptable and feasible and addressed some concerns about testing in clinics.

203 Five studies reported on user values and preferences for FB-HIVST [4,13,17–19]. In all studies, most
204 reported that FB-HIVST was acceptable and feasible and addressed some concerns about testing in
205 clinics. Continuing to receive demonstrations on how to self-test and tailored post-test services as part of
206 FB-HIVST remained important to many [4,19].

207 Common factors for preferring facility-based HIVST included a desire for oral fluid-based testing, interest
208 in trying something new, greater convenience, autonomy and easy access to in-person support if
209 needed. Among adolescent testers in Mozambique [17], 85% (n=253) said they preferred FB-HIVST over
210 the standard HTS with most wanting FB-HIVST because it didn't require a finger prick (56.4%) and
211 enabled access to counselling and privacy from family (76.3%). Truck drivers who opted into FB-HIVST
212 had some similar reasons, with many preferring oral testing (25%), and feeling curious to try something
213 new (89%) [13]. In the general outpatient population, however, most valued FB-HIVST for its speed,
214 convenience, autonomy and easy access to post-test services [4]. Some also felt more motivated to test
215 because they saw others self-testing and that felt that if they had not self-tested at the facility they may
216 not have linked to care [19].

217 Not all individuals preferred FB-HIVST. For those desiring standard testing services, many did not trust
218 oral fluid-based tests or felt they would not be able to self-test correctly [17]. Others, however, preferred

219 to self-test at home instead of at a facility [17], so they could test with a partner, family member or
220 friend [13], and could avoid unwanted disclosure or judgement at facilities [18].

221

222 **Costs and Cost-Effectiveness**

223 Three studies reported on resource use [20–22] and were all in sub-Saharan Africa (see summary in
224 Appendix 3, Supplementary materials). In one multi-country study [21], the average cost per HIVST kit
225 distributed in facilities was less than or equal to home-based HIVST. And in a costing study which used
226 data from a RCT [20], FB-HIVST had a higher average incremental cost per person tested, per person
227 newly diagnosed, and per patient initiated on ART, than standard HTS. However, when results were
228 adapted and modelled to public health clinics, the average unit costs for FB-HIVST was more comparable
229 to standard testing. Despite somewhat higher costs than standard facility-based HTS, when using this
230 same data a modelling study found that when assuming a threshold analysis of \$200 USD (2017) per new
231 diagnosis, FB-HIVST would be cost-effective and potentially cost-saving if lower cost HIVST kits (\$1.80-
232 1.00) were used or if FB-HIVST was limited to individuals who had not tested in the past year [22].

233 Consumables and staffing costs were the main cost drivers of FB-HIVST. However, time and motion data
234 from one study [4] did identify that FB-HIVST be used to reduce provider time by 36-53% and thereby
235 lead to cost-savings in facilities.

236 **Discussion**

237 HIVST has become a critical tool for maintaining essential services and expanding access to testing,
238 prevention, and care. This systematic review and meta-analysis indicate low certainty evidence that FB-
239 HIVST, compared to standard testing, increases testing uptake and diagnoses, proving acceptable and
240 potentially affordable, especially in low-income countries. These findings align with previous reviews on
241 the effectiveness of HIVST across settings, populations, and implementation strategies.

242 FB-HIVST has demonstrated potential in promoting testing uptake and diagnosis. Amidst the challenges
243 posed by the COVID-19 pandemic, FB-HIVST emerged as an effective tool, showcasing its relevance for
244 future pandemic preparedness and addressing human resource-constraints [5,6]. The results from this
245 review further signal an opportunity for FB-HIVST to replace risk-based screening tools, for which, recent
246 data suggests may inadvertently reduce testing coverage, diagnosis, and ART initiations [8]. FB-HIVST
247 would offer a streamlined and more accessible alternative, especially in settings with complex risk-
248 screening protocols.

249 Additionally, the systematic review found that FB-HIVST affords users the customary benefits associated
250 with self-testing, such as convenience, autonomy, and ease of use, while also providing the added
251 advantage of integrating post-test facility-based services. Notably, a more recent qualitative study has
252 also found that FB-HIVST may help overcome traditional facility-based barriers to HIV testing [23].
253 Analysis on acceptability reveals that individuals expressing a preference for FB-HIVST exhibit an
254 inclination towards oral testing. It is noteworthy, that not all HIV self-tests are oral, and existing literature
255 highlights the acceptance of blood-based self-tests [24–26]. Optimizing FB-HIVST implementation
256 requires strategies for private and convenient service delivery, such as provision of private self-testing
257 spaces [23]. The significance of demonstrations and sensitization in enhancing user experience should
258 also leveraged, acknowledging that various HIVST methods remain essential to cater to diverse
259 preferences and needs.

260 Linkage to care evidence was drawn from a single trial. On one hand, linkage to care among total
261 participants enrolled in the study, was over three times as likely in FB-HIVST than standard HTS, driven by
262 the greater number of people diagnosed with HIV through FB-HIVST. On the other hand, linkage to care
263 rates among people newly diagnosed with HIV may be lesser in FB-HIVST than standard HTS. In other
264 words, the interpretation of linkage to care may vary depending on the analysis conducted. In short,
265 despite FB-HIVST's potential to diagnose and link more people to care overall, it still introduces a risk of

266 loss-to-follow-up as linkage to care is contingent on self-reporting. FB-HIVST may thus necessitate follow-
267 up strategies such as providing HIVST kits with linkage to care information, and in-person or remote post-
268 test counselling services [30]. Notably, no study reported on linkage to prevention services. Given the
269 new recommendation to integrate HIVST to Pre-Exposure Prophylaxis (PrEP) services [31], it is important
270 for future studies to further examine strategies for linkage to prevention services.

271 Only one cohort study compared the diagnostic accuracy of FB-HIVST to the results of confirmatory
272 finger-prick tests. Overall accuracy was high, though there were some occurrences of diagnostic
273 discrepancies (2%, n=6/299). Other studies evaluating user's interpretations of HIVST results have
274 similarly found users less likely to correctly interpret invalid and weak positive results, both for oral fluid
275 and blood-based/finger-prick HIVST [32,33]. In the case of FB-HIVST, the potential to support clients in
276 their interpretation of HIVST may be more readily available in the facility. Nevertheless, sensitization and
277 demonstrations, as well as written and visual aids should be further explored to support all HIVST clients.
278 Furthermore, the increasing use of videos and alternative instructional methods, informed by lessons
279 learned during the COVID-19 pandemic, hold promise for enhancing HIVST accuracy.

280 FB-HIVST extends beyond HIV diagnostics, potentially contributing to broader self-care and self-testing
281 models. As evidenced by emerging options such as the dual HIV/Syphilis self-test kits, FB-HIVST sets a
282 precedent for integrating multiple disease screenings in a single, unified step. This innovation suggests
283 potential applications across other disease programs, with opportunities for adaptation to areas such as
284 COVID-19, Hepatitis C infection, and other sexually transmitted infections. The scalability and
285 adaptability of FB-HIVST may present an exciting prospect for streamlining diagnostic processes,
286 enhancing accessibility, and ultimately improving greater public health outcomes.

287 In regard to costs, the availability of a \$1 USD HIVST listed by WHO prequalification [34] marks progress
288 in affordability and accessibility. While early evidence signals FB-HIVST may help save health worker

289 time, it is important to further investigate the full costs of this approach in real-world settings, including
290 in cases where pre-testing demonstrations and optional support to self-test users are provided.
291 Understanding how time and resources can be adjusted to maximize potential savings is crucial to
292 support effective use of this testing approach. Finally, costs of FB-HIVST across low and high-burden
293 settings may be further investigated to ascertain whether the intervention remains cost-effective across
294 different settings.

295 This review was limited by the number of trials which directly compared FB-HIVST to standard HTS so
296 that meta-analysis could only be performed for two reported outcomes. Certainty of evidence was
297 commonly downgraded to low due to high risk of bias and imprecision, driven by confidence intervals
298 encompassing the null effect. The studies were primarily conducted in east and southern Africa and may
299 thus not be generalizable to other settings. Further research is needed to evaluate whether the costs
300 and benefits of FB-HIVST hold true in low-burden settings, where progress toward testing and treatment
301 targets may lag. This exploration is crucial, particularly in contexts where FB-HIVST could offer new
302 testing opportunities to underserved populations, such as men and adolescents. Likewise, while
303 information on resource use was identified it was very limited.

304 Based on the findings of this review, coupled with additional evidence reviewed at an expert meeting,
305 WHO recommended in July 2023, that FB-HIVST be offered as an additional option for testing in facilities
306 [31]. Ultimately, HIVST can continue to play an important role in increasing access to HIV testing services,
307 driving case-finding efforts to reach those who have not yet benefitted from HIV testing, and promoting
308 efficiency in resource-constrained environments.

309 **Conclusion**

310 This review found FB-HIVST may be a safe, acceptable, and effective method to increase HIV testing
311 coverage and diagnosis. These findings are particularly relevant for clinical settings with high HIV burden

312 and limited staff and resources and where there continues to be gaps in HIV testing service delivery.
313 Based on these findings, WHO now recommends FB-HIVST be offered as an additional testing option in
314 facilities. HIVST does not replace provider-administered testing for those with reactive results.
315 Individuals with a reactive self-test result should receive further testing from a trained provider using the
316 full national testing algorithm. Further research on ways to optimise service delivery, linkage to
317 prevention and care and allocation of limited resources remain a priority.

Competing interests

We declare no competing or conflict of interest.

Authors' contribution

CJ and MSJ conceived and provided overall guidance to review. KVM conducted screening, data extraction, analysis, with support from CJ, MSJ, and NS. KVM and CJ drafted the manuscript, and all authors MSJ, NS, BMR, MBDC, RB, and CJ contributed, read, and approved the final version.

Acknowledgements

We would like to thank Margaret Crampton for her assistance with the screening stage of this review as well as the World Health Organization guideline development group members for their contributions.

Funding

This systematic review was supported by Unitaid-WHO HIV and Co-Infections/Co-Morbidities Enabler Grant [HIV&COIMS], 541 no grant number; <https://unitaid.org>)

Data Availability Statement

The data extracted for this systematic review are available within the article and its supplementary materials.

References

1. World Health Organization. Guidelines on HIV Self-Testing and Partner Notification: Supplement to Consolidated Guidelines on HIV Testing Services. Geneva: World Health Organization; 2016.
2. Prequalified In Vitro Diagnostics | WHO - Prequalification of Medical Products (IVDs, Medicines, Vaccines and Immunization Devices, Vector Control) [Internet]. [cited 2023 Jul 25]. Available from: <https://extranet.who.int/pqweb/vitro-diagnostics/vitro-diagnostics-lists>
3. Joint United Nations Programme on HIV/AIDS. Laws and Policies Analytics | Home [Internet]. [cited 2023 Jul 25]. Available from: <https://lawsandpolicies.unaids.org/>
4. Dovel K, Shaba F, Offorjebe OA, Balakasi K, Nyirenda M, Phiri K, et al. Effect of facility-based HIV self-testing on uptake of testing among outpatients in Malawi: a cluster-randomised trial. *Lancet Glob Health*. 2020 Feb;8(2):e276–87.
5. World Health Organization. Maintaining essential health services: operational guidance for the COVID-19 context: interim guidance. 2020 Jun 1;
6. Considerations for HIV self-testing in the context of the COVID-19 Pandemic and its response: an operational update. 2020 Jun [cited 2023 Jul 26];41. Available from: https://media.path.org/documents/Considerations-for-HIV-Self-Testing-in-the-Context-of-the-COVID-19-Pandemic-an_mvO4Y2E.pdf?_gl=1*1ctqgse*_gcl_au*NjA4MjExMjk1LjE2OTAzNzgxOTA.*_ga*NDE2MTE2NzEuMTY5MDM3ODE5MA..*_ga_YBSE7ZKDQM*MTY5MDM3ODE5MC4xLjAuMTY5MDM3ODE5MC42MC4wLjA.
7. Ong JJ, Coulthard K, Quinn C, Tang MJ, Huynh T, Jamil MS, et al. Risk-Based Screening Tools to Optimise HIV Testing Services: a Systematic Review. *Curr HIV/AIDS Rep*. 2022 Apr;19(2):154–65.
8. Ginivan M, Guerra K, Lubega M, Senyama G, Musoke A, Geoffrey T, et al. Performance of an HIV risk screening tool to identify people living with HIV aged 15 years and above in primary care facilities in Uganda: a secondary program data analysis. 2021.
9. Grimsrud A, Wilkinson L, Ehrenkranz P, Behel S, Chidarikire T, Chisenga T, et al. The future of HIV testing in eastern and southern Africa: Broader scope, targeted services. *PLoS Med*. 2023 Mar 14;20(3):e1004182.
10. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. *Cochrane Handbook for Systematic Reviews of Interventions* version 6.3 (updated February 2022). [Internet]. Cochrane. 2022 [cited 2023 Jan 17]. Available from: <http://www.training.cochrane.org/handbook>
11. Schünemann H, Brożek J, Guyatt G, Oxman A, editors. *Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach* [Internet]. The GRADE Working Group; 2013 Oct [cited 2023 Jan 17]. Available from: <http://guidelinedevelopment.org/handbook>
12. Santesso N, Glenton C, Dahm P, Garner P, Akl EA, Alper B, et al. GRADE guidelines 26: informative statements to communicate the findings of systematic reviews of interventions. *J Clin Epidemiol*. 2020 Mar;119:126–35.

13. Kelvin EA, George G, Mwai E, Nyaga E, Mantell JE, Romo ML, et al. Offering self-administered oral HIV testing to truck drivers in Kenya to increase testing: a randomized controlled trial. *AIDS Care*. 2018 Jan;30(1):47–55.
14. Kelvin EA, George G, Kinyanjui S, Mwai E, Romo ML, Oruko F, et al. Announcing the availability of oral HIV self-test kits via text message to increase HIV testing among hard-to-reach truckers in Kenya: a randomized controlled trial. *BMC Public Health*. 2019 Jan 3;19(1):7.
15. Kelvin EA, George G, Mwai E, Kinyanjui S, Romo ML, Odhiambo JO, et al. A Randomized Controlled Trial to Increase HIV Testing Demand Among Female Sex Workers in Kenya Through Announcing the Availability of HIV Self-testing Via Text Message. *AIDS Behav*. 2019 Jan;23(1):116–25.
16. Gaydos CA, Solis M, Hsieh Y-H, Jett-Goheen M, Nour S, Rothman RE. Use of tablet-based kiosks in the emergency department to guide patient HIV self-testing with a point-of-care oral fluid test. *Int J STD AIDS*. 2013 Sep;24(9):716–21.
17. Hector J, Davies M-A, Dekker-Boersema J, Aly MM, Abdalad CCA, Langa EBR, et al. Acceptability and performance of a directly assisted oral HIV self-testing intervention in adolescents in rural Mozambique. *PLoS ONE*. 2018 Apr 5;13(4):e0195391.
18. Mphande M, Campbell P, Hoffman RM, Phiri K, Nyirenda M, Gupta SK, et al. Barriers and facilitators to facility HIV self-testing in outpatient settings in Malawi: a qualitative study. *BMC Public Health*. 2021 Dec 2;21(1):2200.
19. Hubbard JA, Mphande M, Phiri K, Balakasi K, Hoffman RM, Daniels J, et al. Improving ART initiation among men who use HIV self-testing in Malawi: a qualitative study. *J Int AIDS Soc*. 2022 Jun;25(6):e25950.
20. Nichols BE, Offorjebe OA, Cele R, Shaba F, Balakasi K, Chivwara M, et al. Economic evaluation of facility-based HIV self-testing among adult outpatients in Malawi. *J Int AIDS Soc*. 2020 Sep;23(9):e25612.
21. Sande LA, Matsimela K, Mwenge L, Mangenah C, Choko AT, d'Elbée M, et al. Costs of integrating HIV self-testing in public health facilities in Malawi, South Africa, Zambia and Zimbabwe. *BMJ Glob Health*. 2021 Jul;6(Suppl 4).
22. Nichols BE, de Nooy A, Benade M, Balakasi K, Mphande M, Rao G, et al. Facility-based HIV self-testing strategies may substantially increase number of men and youth tested for HIV in Malawi: results from a data-driven individual-based model. *medRxiv*. 2021 Aug 27;
23. Shaba F, Balakasi K, Offorjebe OA, Nyirenda M, Wong VJ, Gupta SK, et al. Facility HIV self-testing in outpatient departments: an assessment of characteristics and concerns of outpatients who opt-out of testing in Malawi. *J Acquir Immune Defic Syndr*. 2023 Nov 15;
24. Lippman SA, Gilmore HJ, Lane T, Radebe O, Chen Y-H, Mlotshwa N, et al. Ability to use oral fluid and fingerstick HIV self-testing (HIVST) among South African MSM. *PLoS ONE*. 2018 Nov 8;13(11):e0206849.

25. Shapiro AE, van Heerden A, Krows M, Sausi K, Sithole N, Schaafsma TT, et al. An implementation study of oral and blood-based HIV self-testing and linkage to care among men in rural and peri-urban KwaZulu-Natal, South Africa. *J Int AIDS Soc.* 2020 Jun;23 Suppl 2:e25514.
26. Trabwongwitaya P, Songtaweessin WN, Paiboon N, Wongharn P, Moonwong J, Phiphatkhunarnon P, et al. Preference and ability to perform blood-versus oral-fluid-based HIV self-testing in adolescents and young adults in Bangkok. *Int J STD AIDS.* 2022 Apr;33(5):492–8.
27. Njau B, Damian DJ, Abdullahi L, Boulle A, Mathews C. The effects of HIV self-testing on the uptake of HIV testing, linkage to antiretroviral treatment and social harms among adults in Africa: A systematic review and meta-analysis. *PLoS ONE.* 2021 Jan 27;16(1):e0245498.
28. Hlongwa M, Hlongwana K, Makhunga S, Choko AT, Dzinamarira T, Conserve D, et al. Linkage to HIV Care Following HIV Self-testing Among Men: Systematic Review of Quantitative and Qualitative Studies from Six Countries in Sub-Saharan Africa. *AIDS Behav.* 2023 Feb;27(2):651–66.
29. Johnson CC, Kennedy C, Fonner V, Siegfried N, Figueroa C, Dalal S, et al. Examining the effects of HIV self-testing compared to standard HIV testing services: a systematic review and meta-analysis. *J Int AIDS Soc.* 2017 May 15;20(1):21594.
30. Ma P, Shoki R, Su X, Ota E. Implementation strategies to promote linkage to care for key populations after HIV self-testing: a scoping review. *J Glob Health Rep.* 2022 Dec 5;6.
31. WHO recommends optimizing HIV testing services [Internet]. [cited 2023 Jul 27]. Available from: <https://www.who.int/news/item/22-07-2023-who-recommends-optimizing-hiv-testing-services>
32. Mogere P, Bardon AR, Kiptinness C, Magara R, Ongachi S, Mbaire S, et al. Interpretation of HIV self-test results among PrEP users in Kenya. 2022 [cited 2023 Jul 27]. p. Poster-T03. Available from: <https://www.croiconference.org/abstract/interpretation-of-hiv-self-test-results-among-prep-users-in-kenya/>
33. Peck RB, Lim JM, van Rooyen H, Mukoma W, Chepuka L, Bansil P, et al. What should the ideal HIV self-test look like? A usability study of test prototypes in unsupervised HIV self-testing in Kenya, Malawi, and South Africa. *AIDS Behav.* 2014 Jul;18 Suppl 4:S422-32.
34. New US\$ 1 price for HIV self-tests [Internet]. [cited 2023 Nov 28]. Available from: <https://www.who.int/news/item/27-07-2022-new-1-dollar-price-for-hiv-self-tests>